KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme (CME) Other Non-Current Liabilities (2016 - 2025)

Cme (CME) has disclosed Other Non-Current Liabilities for 17 consecutive years, with $734.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 1.89% to $734.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $734.8 million, a 1.89% increase, with the full-year FY2025 number at $734.8 million, up 1.89% from a year prior.
  • Other Non-Current Liabilities was $734.8 million for Q4 2025 at Cme, up from $725.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.1 billion in Q1 2021 to a low of $720.2 million in Q2 2025.
  • A 5-year average of $833.7 million and a median of $817.2 million in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: fell 17.55% in 2022, then rose 1.89% in 2025.
  • Cme's Other Non-Current Liabilities stood at $896.5 million in 2021, then fell by 7.86% to $826.0 million in 2022, then decreased by 3.37% to $798.2 million in 2023, then fell by 9.65% to $721.2 million in 2024, then increased by 1.89% to $734.8 million in 2025.
  • Per Business Quant, the three most recent readings for CME's Other Non-Current Liabilities are $734.8 million (Q4 2025), $725.7 million (Q3 2025), and $720.2 million (Q2 2025).